Retina & Macular Diseases
Three decades of Retina research. Proven models. Trusted results.
New therapies. New modalities. Greater urgency. Retina & Macular Diseases are leading causes of vision loss and blindness worldwide.
With aging populations, rising incidences of hypertension and diabetes, and increasing rates of autoimmune disease, the need for novel therapies is greater than ever.
Illumination of the healthy retina
We’ve shaped our team to meet the moment.
For over thirty years, our team of Retina & Macular Disease specialists have successfully navigated the retinal research landscape — guiding clients across all phases of development to ensure the highest likelihood of clinical success. In the past 5 years alone, the Retina & Macular Disease team ran 135+ programs across all phases of the developmental pipeline. Our team of Retina & Macular Disease specialists will guide you through every step of the regulatory and approval process, ensuring a smooth and successful journey from start to finish.
Partner with Ora, the ophthalmology research company and get your best in class Retina & Macular Disease therapeutic to market.
Key Indications
Wet Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration
Geographic Atrophy
Diabetic Retinopathy
Diabetic Macular Edema
Retinal Vein Occlusion
Retinitis Pigmentosa
Leber Congenital Amaurosis
Ushers
Retinal Dystrophy
Stargardt Disease
The Ora Retina & Macular Disease Team Leaders
Keith Lane
Senior Vice President, Posterior Segment
20+ years’ experience in Retinal & Macular Disease pharmaceutical development
Expert in developing innovative endpoints and trial designs for retinal diseases, advancing clinical research methodologies in IRDs and FDA accepted mobility tests
Published extensively on retinal diseases and clinical trial advancements, including FDA-accepted mobility tests
Dr. Alex McKeown
Retina Specialist / Expert
PhD in vision science and retinal imagining techniques
10+ years in ophthalmology drug development and research, including at Apellis with key role getting first GA product approved by FDA as well as at Novartis and Heidelberg
Expertise in retinal image analysis, with prior roles as reader both for Duke and BIRC Reading centers
Ora Retinal & Macular Disease experience over the last 5 Years
Patients enrolled
Sites activated
Programs
The Ora Retina & Macular Disease team’s comprehensive expertise spans early-phase clinical trials to late-stage studies. Our strategic regulatory guidance and efficient operational execution, ensures seamless trial progression through even the most complex development pathways.
Why Sponsors with therapies in the Retina & Macular Disease pipeline choose to partner with Ora
A sample of Ora successes
Expert end-to-end Retina & Macular Disease therapeutic pipeline highlights
A Diabetic Macular Edema (DME) drug 
approval in the United States in 2023 [innovative decoy receptor that binds VEGF-A], showcasing Ora’s ability to guide Retina & Macular Disease therapeutics from concept to approval.
Proven ability to accelerate enrollment in Retina & Macular Disease studies:
nAMD Phase 1 clinical trial completed enrollment two months ahead of schedule.
dAMD/GA Phase 2 program finished enrollment one month ahead of scheduled timeline.
The Ora Visual Navigation Challenge (VNC™) Mobility Course
The Ora-VNC™ was created to serve as a functional endpoint to evaluate cell and gene therapies (CGT) efficacy in treating inherited retinal diseases (IRDs).
Since the technology’s inception, the VNC™ mobility course has been used in 20+ clinical trials as a clinical endpoint.
